Everest Medicines (HKSE:01952) FFO


HKSE:01952 Everest Medicines Ltd HKSE:01952
42 GF Score
Price HK$26.92
GF Value HK$292.01
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Everest Medicines FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01952
42GF Score
Everest Medicines Ltd HKSE:01952
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Everest Medicines (HKSE:01952) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of HK$26.92 is trading 90.8% below its estimated GF Value™ of HK$292.01. GuruFocus considers Everest Medicines to be Possible Value Trap.

Key valuation signals for HKSE:01952:

  • FFO:
  • GF Value™: HK$292.01 vs. price of HK$26.92 (90.8% below fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Everest Medicines Business Description

Other Exchanges 6HN:Germany
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
42GF Score

Get the complete analysis for HKSE:01952

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$26.92
Price
HK$292.01
GF Value